Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 9/20 | 0.40 |
| ▸ | TCF7L2 | Q9NQB0 | 9/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.37 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.37 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116329 | 0.92 | CTNNB1 (0.41) | CTNNB1TCF7L2KDM4EPOLBJAK2 | |
| SCHEMBL5110248 | 0.91 | CTNNB1 (0.41) | CTNNB1TCF7L2ALDH1A1MAPTRXFP1 | |
| SCHEMBL5121622 | 0.89 | CTNNB1 (0.40) | CTNNB1TCF7L2POLBMAPTRXFP1 | |
| SCHEMBL14131735 | 0.87 | CTNNB1 (0.39) | CTNNB1TCF7L2POLBALDH1A1MAPT | |
| SCHEMBL5123850 | 0.87 | MAPT (0.43) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL14131671 | 0.86 | SSTR5 (0.43) | CTNNB1TCF7L2POLBALDH1A1MAPT | |
| SCHEMBL14131725 | 0.86 | CTNNB1 (0.44) | CTNNB1TCF7L2POLBHDAC1MEN1 | |
| SCHEMBL5114661 | 0.85 | VNN1 (0.39) | CTNNB1TCF7L2HDAC1HDAC6MAPT | |
| SCHEMBL5117245 | 0.85 | VNN1 (0.39) | CTNNB1TCF7L2HDAC1HDAC6MAPT | |
| SCHEMBL14140183 | 0.85 | CTNNB1 (0.40) | CTNNB1TCF7L2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PNP | CTNNB1 1384/4885TCF7L2 3616/4885KDM4E 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.